GlassScriptPhysician profile
Michael J Bloch
NPI 1508970195
$474,923.43
in general payments reported to CMS, 2019-2025
21 companies · $144K in 2025
The $144K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82K · 2020: $31K · 2021: $51K · 2022: $45K · 2023: $40K · 2024: $83K · 2025: $144K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $103K · Consulting Fee: $96K · Travel and Lodging: $60K · Food and Beverage: $6,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $103,025.00 |
| Consulting Fee | $96,355.00 |
| Travel and Lodging | $60,380.12 |
| Food and Beverage | $6,357.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $180,520.77 | 2021-2025 | Symplicity G3 |
| Janssen Pharmaceuticals, INC | $99,352.21 | 2019-2023 | Xarelto |
| Recor Medical INC | $41,765.93 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Idorsia Pharmaceuticals US INC | $32,553.23 | 2023-2025 | Tryvio, Aprocitentan, Tryvio |
| Esperion Therapeutics, INC. | $29,448.55 | 2020-2024 | Nexletol, Nexlizet |
| Amgen INC. | $21,960.15 | 2019-2024 | Repatha |
| Corcept Therapeutics | $21,491.53 | 2024-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $15,012.05 | 2020-2025 | Leqvio |
| E.R. Squibb & Sons, L.L.C. | $7,488.39 | 2020-2022 | |
| Medtronic Vascular, INC. | $6,219.89 | 2019-2020 | |
| Johnson & Johnson Health Care Systems INC. | $5,360.00 | 2022 | |
| Amarin Pharma, INC. | $5,231.09 | 2019-2020 | |
| Boston Scientific Corporation | $4,310.16 | 2024-2025 | General - Therapies, Watchman Access System |
| Vifor Pharma, INC. | $3,678.40 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $311.78 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $85.19 | 2024 | Praluent, Evkeeza |
| Biogen, INC. | $58.72 | 2025 | Vumerity, Tysabri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.23 | 2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $18.44 | 2023 | |
| Merck Sharp & Dohme LLC | $12.72 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bloch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.